Wall Street brokerages forecast that Catalyst Pharmaceuticals (NASDAQ:CPRX) will report ($0.06) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Catalyst Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.05) and the lowest estimate coming in at ($0.07). Catalyst Pharmaceuticals also posted earnings of ($0.06) per share in the same quarter last year. The company is scheduled to report its next quarterly earnings results on Wednesday, May 9th.
On average, analysts expect that Catalyst Pharmaceuticals will report full year earnings of ($0.36) per share for the current financial year, with EPS estimates ranging from ($0.58) to ($0.23). For the next financial year, analysts forecast that the firm will report earnings of ($0.11) per share, with EPS estimates ranging from ($0.23) to ($0.01). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Catalyst Pharmaceuticals.
Catalyst Pharmaceuticals (NASDAQ:CPRX) last announced its quarterly earnings data on Wednesday, March 14th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.06).
Shares of NASDAQ:CPRX opened at $2.37 on Thursday. Catalyst Pharmaceuticals has a 12-month low of $1.62 and a 12-month high of $4.51.
In other Catalyst Pharmaceuticals news, insider Patrick J. Mcenany bought 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, April 3rd. The shares were bought at an average cost of $2.29 per share, with a total value of $45,800.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 9.60% of the stock is owned by company insiders.
Institutional investors have recently bought and sold shares of the business. Emerald Advisers Inc. PA bought a new stake in Catalyst Pharmaceuticals during the 4th quarter valued at approximately $5,364,000. Alps Advisors Inc. bought a new stake in Catalyst Pharmaceuticals during the 4th quarter valued at approximately $435,000. EAM Investors LLC bought a new stake in Catalyst Pharmaceuticals during the 4th quarter valued at approximately $4,076,000. OxFORD Asset Management LLP boosted its position in Catalyst Pharmaceuticals by 60.5% during the 3rd quarter. OxFORD Asset Management LLP now owns 138,329 shares of the biopharmaceutical company’s stock valued at $344,000 after acquiring an additional 52,161 shares in the last quarter. Finally, Crestline Management LP bought a new stake in Catalyst Pharmaceuticals during the 3rd quarter valued at approximately $562,000. 54.66% of the stock is currently owned by institutional investors and hedge funds.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.